March 8 (Reuters) - Incyte Corp INCY.O:
INCYTE ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIALS EVALUATING RUXOLITINIB CREAM 1.5% (OPZELURA®) IN PATIENTS WITH PRURIGO NODULARIS (PN) AT 2025 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING
INCYTE CORP - PHASE 3 TRUE-PN1 STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS
INCYTE - TOPLINE DATA FROM SEPARATE PHASE 3 STUDY, TRUE-PN2, SHOWED THAT PRIMARY ENDPOINT DID NOT REACH STATISTICAL SIGNIFICANCE